Adverum Biotechnologies (ADVM) Competitors $5.07 -0.26 (-4.79%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. DSGN, DRUG, ANNX, LXEO, BNTC, DMAC, ALT, CGEM, RCKT, and LBRXShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), Annexon (ANNX), Lexeo Therapeutics (LXEO), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), Altimmune (ALT), Cullinan Therapeutics (CGEM), Rocket Pharmaceuticals (RCKT), and LB Pharmaceuticals (LBRX). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Design Therapeutics Bright Minds Biosciences Annexon Lexeo Therapeutics Benitec Biopharma DiaMedica Therapeutics Altimmune Cullinan Therapeutics Rocket Pharmaceuticals LB Pharmaceuticals Adverum Biotechnologies (NASDAQ:ADVM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do insiders and institutionals have more ownership in ADVM or DSGN? 48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 23.5% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend ADVM or DSGN? Adverum Biotechnologies currently has a consensus price target of $19.75, suggesting a potential upside of 289.93%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Adverum Biotechnologies is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher valuation & earnings, ADVM or DSGN? Design Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Design Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M106.26-$130.93M-$7.85-0.65Design TherapeuticsN/AN/A-$49.59M-$1.12-6.08 Does the media refer more to ADVM or DSGN? In the previous week, Adverum Biotechnologies had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Adverum Biotechnologies and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.83 beat Adverum Biotechnologies' score of 0.63 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ADVM or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -297.29% -101.40% Design Therapeutics N/A -27.15%-26.07% Which has more risk & volatility, ADVM or DSGN? Adverum Biotechnologies has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. SummaryDesign Therapeutics beats Adverum Biotechnologies on 8 of the 14 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.26M$3.36B$6.12B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-0.6522.1586.1127.75Price / Sales106.26419.64588.17183.92Price / CashN/A47.1938.3262.20Price / Book1.4910.3912.976.80Net Income-$130.93M-$52.40M$3.30B$275.97M7 Day Performance-6.03%4.11%3.27%2.08%1 Month Performance53.02%15.96%10.12%9.09%1 Year Performance-31.92%33.37%83.41%36.72% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies3.8118 of 5 stars$5.07-4.8%$19.75+289.9%-29.3%$106.26M$1M-0.65190Analyst ForecastDSGNDesign Therapeutics0.1944 of 5 stars$6.85+4.3%N/A+52.1%$374.15MN/A-6.1240News CoverageAnalyst ForecastDRUGBright Minds Biosciences3.0297 of 5 stars$57.45+9.0%$81.00+41.0%+5,724.2%$371.36MN/A-61.77N/APositive NewsANNXAnnexon2.9235 of 5 stars$3.12-7.4%$12.50+300.6%-53.1%$370.32MN/A-2.4260Positive NewsAnalyst ForecastHigh Trading VolumeLXEOLexeo Therapeutics2.8227 of 5 stars$6.66-1.6%$15.33+130.2%-3.5%$365.59M$650K-2.0458Positive NewsAnalyst ForecastAnalyst RevisionBNTCBenitec Biopharma1.9951 of 5 stars$13.99+2.1%$24.80+77.3%+53.3%$359.63M$80K-9.5220Analyst ForecastDMACDiaMedica Therapeutics2.1069 of 5 stars$6.91-0.4%$12.33+78.5%+56.0%$358.72MN/A-10.0120Positive NewsAnalyst ForecastALTAltimmune3.0245 of 5 stars$3.79-5.3%$17.40+359.1%-34.5%$353.03M$20K-3.2150Analyst ForecastCGEMCullinan Therapeutics2.4903 of 5 stars$5.97+0.2%$26.00+335.5%-54.4%$352.08MN/A-1.8530Analyst ForecastRCKTRocket Pharmaceuticals4.763 of 5 stars$3.28+0.6%$16.73+410.2%-77.9%$351.77MN/A-1.31240Analyst ForecastLBRXLB PharmaceuticalsN/A$15.24-1.3%N/AN/A$346.52MN/A0.0016News CoverageAnalyst UpgradeAnalyst RevisionGap Down Related Companies and Tools Related Companies DSGN Alternatives DRUG Alternatives ANNX Alternatives LXEO Alternatives BNTC Alternatives DMAC Alternatives ALT Alternatives CGEM Alternatives RCKT Alternatives LBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
